H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Cardiff Oncology (CRDF) to $13 from $14 and keeps a Buy rating on the shares. The firm says the initial CRDF-004 trial readout us expected by end of 2024.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter